For clinics, med spas and telehealth. And everyone in peptides and longevity.

Friday, Nov. 13, 2026

Terry Dubrow's HealthRX starts selling six peptides

Also today: LifeMD cuts its 2026 revenue outlook

HealthRX, a telehealth seller, lists all six peptides from HHS's draft compounding policy on its homepage: BPC-157, TB-500, MOTS-c, Epitalon, Semax nasal spray and KPV. Each needs a prescription after an online review. The page says a state-licensed 503A pharmacy makes them. The peptide offer runs $99 for the first month on a plan, then from $129 a month on a 12-month plan, or $199 month to month. Compounded semaglutide and tirzepatide are $39 for the first month.

Take. HealthRX, a national seller with a TV surgeon in its ads, prices BPC-157 at $129 a month on a yearly plan and $199 month to month. Peptide patients will quote those numbers back to you. Before your next peptide consult, put your price next to them and name what the difference buys.

Cash GLP-1 prices

See all prices

Semaglutide per month

3 of 82 prices shown

ODR Price Board optimized.news, checked Nov. 2-12, 2026

All-in totalMedicineMembershipAll-in median

SellerPer monthAll-in median $175Read
OurView HealthSemaglutideCompoundedMedication, online consultation, shipping options
All-in $109 , lowest third
Bayan HealthSemaglutide + vitamin B6CompoundedMedication, physician consultation, free expedited shipping; labs only "if needed"
All-in $129 , lowest third
FrontCareSemaglutideCompoundedProvider review, medication, syringes/supplies, 2-day shipping
All-in $229 , highest third

Tirzepatide per month

1 of 77 prices shown

ODR Price Board optimized.news, checked Nov. 2-12, 2026

All-in totalMedicineMembershipAll-in median

SellerPer monthAll-in median $239Read
PreventiveMDTirzepatideCompoundedMedication and provider review
All-in $139 , lowest third

See all 159 GLP-1 compounded prices: sign in or subscribe free.

FDA's peptide compounding policy

HHS's interim policy covers which peptides pharmacies can compound. HHS filed the policy with the Federal Register on Oct. 28, 2026. It published Oct. 30, with comments open for two weeks after that.

From OIRA's meeting log, checked . The log marks each meeting "Scheduled." No materials are posted.

Read where the policy stands

More from Friday's issue

Recent issues

Search past issues

Friday, Nov. 13, 2026

Terry Dubrow's HealthRX starts selling six peptides

Also: LifeMD cuts its 2026 revenue outlook

Thursday, Nov. 12, 2026

Hims & Hers to start selling peptides this month

Also: California halts a Tampa pharmacy's shipments

Wednesday, Nov. 11, 2026

Oura agrees to buy AI care practice Counsel Health

Also: LifeMD delays its 10-Q to fix revenue

Tuesday, Nov. 10, 2026

FDA adds eye-risk warning to every approved GLP-1 label

Also: Hims revenue up 49%, ad spend up 6.5%

Monday, Nov. 9, 2026

Lilly puts Zepbound and Foundayo on Hims

Also: Zepbound from $299, Foundayo from $149 on Hims